Policy

BIO advocates for laws, funding and other governmental actions that ensure that biotechnology companies are able to focus on their research whether it be developing next-generation drugs, the next major advancement in agriculture or fuel to move the world...

Press Releases
November 14, 2024
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served by strong leadership that respects and advances…
November 13, 2024
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This promising update supports the latest advancements in…
November 12, 2024
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient and appropriate under the statute," said BIO's EVP…
BIO Advocacy Toolkit

We’ve made it easier for you to access information and share content about biotechnology and prescription medicines. Learn more about dozens of topics and then share information you discover on Twitter, Facebook, and LinkedIn.

BIO Advocate Toolkit
Become an Advocate for Biotechnology
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.